OptimizeRx Reports Strong Fourth Quarter and Full Year 2025 Financial Results
Rhea-AI Summary
OptimizeRx (Nasdaq: OPRX) reported strong Q4 and full-year 2025 results with Q4 revenue $32.2M, full-year revenue $109.4M (19% YoY), and record Q4 net income $5.0M and Q4 adjusted EBITDA $12.0M. The board authorized a $10M share repurchase program and 2026 guidance was set to $109M–$114M revenue and $21M–$25M adjusted EBITDA.
Cash was $23.4M at year-end, operating cash flow improved, and the company reduced term loan principal by $2M.
Positive
- Full-year revenue of $109.4M, up 19% year-over-year
- Q4 adjusted EBITDA record of $12.0M, boosting profitability
- Full-year adjusted EBITDA of $24.3M, implying >20% margin
- Board-authorized $10M share repurchase program effective March 12, 2026
- Year-end cash of $23.4M and $18.7M net operating cash provided
Negative
- Q4 revenue flat at $32.2M versus $32.3M year-ago, showing limited near-term top-line growth
- Net revenue retention declined to 116% from 121%, indicating reduced existing-client growth
- Average revenue per top-20 pharma fell to $2,838 from $2,976, a potential concentration pressure
Market Reaction – OPRX
Following this news, OPRX has gained 5.58%, reflecting a notable positive market reaction. Argus tracked a peak move of +31.1% during the session. Our momentum scanner has triggered 14 alerts so far, indicating notable trading interest and price volatility. The stock is currently trading at $7.95. This price movement has added approximately $7M to the company's valuation. Trading volume is elevated at 2.2x the average, suggesting notable buying interest.
Data tracked by StockTitan Argus (15 min delayed). Upgrade to Silver for real-time data.
Key Figures
Market Reality Check
Peers on Argus
OPRX gained 7.51% while peers were mixed: DH rose 7.46%, SPOK and SY were modestly positive, and TBRG and NRC declined, indicating a stock-specific reaction rather than a sector-wide move.
Previous Earnings Reports
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Nov 06 | Q3 2025 earnings | Positive | -17.4% | Reported Q3 2025 growth, improved profitability, and raised 2025–2026 guidance ranges. |
| Oct 30 | Earnings call scheduling | Neutral | +4.5% | Announced upcoming Q2 2025 results call with full dial-in and webcast details. |
| Aug 07 | Q2 2025 earnings | Positive | +34.7% | Strong Q2 2025 revenue, return to GAAP profitability, and higher full-year guidance. |
| May 12 | Q1 2025 earnings | Positive | +19.7% | Q1 2025 growth, improved losses, and increased 2025 revenue and EBITDA guidance. |
| Mar 12 | Q4 2024 earnings | Positive | +51.7% | Strong Q4 and 2024 results with DAAP expansion and initial 2025 guidance. |
Earnings-related headlines have usually led to positive price reactions, with one notable selloff on strong Q3 2025 results.
Over the last year, OPRX’s earnings cadence has shown steady revenue growth and improving profitability. Q1–Q3 2025 reports highlighted rising revenue, expanding gross profit, and a shift from GAAP losses to income, often accompanied by raised guidance. The strong Q4 and full-year 2025 results with record revenue and adjusted EBITDA extend this trajectory. Historically, most earnings updates (e.g., on Mar 12, May 12, and Aug 7, 2025) saw shares move higher, with the Q3 2025 selloff an exception.
Historical Comparison
Across five recent earnings-related releases, OPRX moved an average of 18.64%. Today’s 7.51% gain is positive but more moderate than prior earnings reactions.
Earnings releases through 2025 showed a steady progression: Q1 and Q2 established double-digit growth and improving margins, Q3 maintained profitability and higher guidance, and Q4/full-year 2025 confirmed record revenue and adjusted EBITDA.
Market Pulse Summary
The stock is up +5.6% following this news. A strong positive reaction aligns with the company’s record Q4 and full-year 2025 results and the announced $10 million buyback. The 7.51% gain is smaller than the average 18.64% move seen after past earnings headlines, but still fits a pattern where most earnings updates have been rewarded. With shares trading well below the $14.49 200-day MA, prior sharp post-earnings swings highlight that volatility around results has been common.
Key Terms
adjusted EBITDA financial
non-GAAP financial
GAAP financial
net revenue retention financial
restricted stock units financial
Rule of 40 financial
AI-generated analysis. Not financial advice.
| - Q4 revenue of |
| - Q4 gross profit increased |
| - Q4 net income and adjusted EBITDA hit records at |
| - Updating 2026 revenue guidance to |
| - Paid off an incremental |
| - OptimizeRx's Board authorizes a |
WALTHAM, Mass., March 05, 2026 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of healthcare technology solutions helping life sciences companies reach and engage healthcare professionals (HCPs) and patients, today announced results for the fourth quarter and full year ended December 31, 2025.
Financial Highlights
- Revenue in the fourth quarter of 2025 remained consistent at
$32.2 million when compared to$32.3 million in the same period of 2024. Full year revenue for 2025 came in at$109.4 million , a19% increase, when compared to$92.1 million in the same year-ago period. - Gross profit in the fourth quarter of 2025 increased
9% year-over-year to$24.1 million from$22.0 million in the same period of 2024. Gross profit for the full year of 2025 was$73.6 million an increase from$59.4 million in the same year-ago period. - GAAP net income in the fourth quarter of 2025 totaled
$5.0 million , or$0.26 per diluted share, compared to net loss of$(0.1) million , or$0.00 per diluted share, in the same period of 2024. GAAP net income for the full year of 2025 totaled$5.1 million , or$0.27 per diluted share, compared to net loss of$(20.1) million , or$(1.10) per diluted share, in the same year-ago period. - Non-GAAP net income in the fourth quarter of 2025 totaled
$9.9 million , or$0.51 per diluted share, compared to$5.5 million , or$0.30 per diluted share in the same period of 2024. Non-GAAP net income in the full year of 2025 came in at$19.9 million , or$1.05 per diluted share, compared to$6.2 million , or$0.33 per diluted share, in the same year-ago period. (see *Non-GAAP Measures below). - Adjusted EBITDA for the fourth quarter of 2025 increased to
$12.0 million compared to$8.8 million in the same period of 2024. Adjusted EBITDA for the full year of 2025 came in at$24.3 million compared to$11.7 million in the same year-ago period. (see *Non-GAAP Measures below). - Cash and cash equivalents was
$23.4 million as of December 31, 2025 as compared to$13.4 million as of December 31, 2024 - Net cash provided by operating activities was
$18.7 million for the year ended December 31, 2025 as compared to$4.9 million in the same period of 2024.
Stephen L. Silvestro, OptimizeRx CEO commented, “We delivered a strong fourth quarter, exceeding both consensus and internal expectations, with revenue of
“We are beginning to see increased market volatility, driven in part by uncertainty surrounding Most Favored Nation (MFN) pricing. In response, we believe some customers are taking a more measured approach to discretionary spending and contract duration. While this dynamic may create some near-term headwinds, we continue to see solid engagement across our network and remain confident in the underlying demand trends supporting our business.
“Against that backdrop, OptimizeRx continues to play a mission-critical role for life sciences companies by enhancing brand visibility, reducing script abandonment, improving interoperability between disparate point-of-care platforms, and supporting the growing shift toward complex specialty medications. In addition, we believe advancements in AI will enable customers to reallocate marketing dollars from content creation toward reach and execution—areas where we provide differentiated value with significant ROIs, further strengthening our position over time.”
| For the Year Ended December 31, | ||||||||
| Key Performance Indicators (KPIs)** | 2025 | 2024 | ||||||
| (in thousands, except percentages) | ||||||||
| Average revenue per top 20 pharmaceutical manufacturers | $ | 2,838 | $ | 2,976 | ||||
| Percent of total revenue attributable to top 20 pharmaceutical manufacturers | 52 | % | 65 | % | ||||
| Net revenue retention | 116 | % | 121 | % | ||||
| Revenue per average full-time employee | $ | 839 | $ | 701 | ||||
Financial Outlook
The Company is also updating its fiscal year 2026 guidance at this time and is expecting revenue to be between
Share Repurchase Program
OptimizeRx’s board of directors has authorized a share repurchase program for up to
Conference Call, Webcast, and Webcast Replay Information
| Date: | Thursday, March 5, 2026 |
| Time: | 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time) |
| Toll Free: | 1-844-825-9789 |
| International: | 1-412-317-5180 |
| Conference ID: | 10206362 |
| Call Me: | https://callme.viavid.com/?$Y2FsbG1lPXRydWUmcGFzc2NvZGU9JmluZm89Y29tcGFueSZyPXRydWUmYj0xNg== |
| Webcast: | https://viavid.webcasts.com/starthere.jsp?ei=1750927&tp_key=099094fd29 |
| Call Me Passcode: | 6586380 |
| Webcast Replay: | The archived webcast will be on the investor relations section of the OptimizeRx website |
Invitation
In an effort to increase relations with institutional investors, OptimizeRx management has dedicated time to hosting individual meetings with portfolio managers and analysts. If you are interested in scheduling a meeting with OptimizeRx management, please contact: adsilva@optimizerx.com or shalper@lifesciadvisors.com.
*Non-GAAP Measures
In addition to the financial measures prepared in accordance with generally accepted accounting principles (GAAP), this earnings release also contains non-GAAP financial measures. The reasons why we believe these measures provide useful information to investors and, for historical periods, a reconciliation of these measures to the most directly comparable GAAP measures are included in the supplemental tables that follow.
Although the Company provides guidance for Adjusted EBITDA, a non-GAAP financial measure, it is not able to provide guidance to the most directly comparable GAAP measure. Reconciliations for forward-looking figures would require unreasonable effort at this time because of the uncertainty and variability of the nature and amount of certain components of various necessary GAAP components, including, for example, those related to compensation, acquisition expenses, other income, amortization or others that may arise during the year, and the Company’s management believes such reconciliations would imply a degree of precision that would be confusing or misleading to investors. For the same reasons, the Company is unable to address the probable significance of the unavailable information.
**Definition of Key Performance Indicators
Top 20 pharmaceutical manufacturers: We have updated the definition of “top 20 pharmaceutical manufacturers” in our key performance indicators to be based upon Fierce Pharma’s most updated list of “The top 20 pharma companies by 2024 revenue”. We previously used “The top 20 pharma companies by 2023 revenue”. As a result of this change, prior periods have been restated for comparative purposes.
Net revenue retention: Net revenue retention is a comparison of revenue generated from all clients in the previous period to total revenue generated from the same clients in the following year (i.e., excludes new client relationships for the most recent year).
Revenue per average full-time employee: We define revenue per average full-time employee (FTE) as total revenue over the last 12 months (LTM) divided by the average number of employees over the LTM, which is calculated by taking our total number of FTEs at the end of the prior year period by our total FTE headcount at the end of the most recent period.
About OptimizeRx
OptimizeRx is a leading healthcare technology company that’s redefining how life science brands connect with patients and healthcare providers. Our platform combines innovative artificial intelligence (AI)-driven tools like the Dynamic Audience Activation Platform (DAAP) and Micro-Neighborhood Targeting (MNT) to deliver timely, relevant, and hyper-local engagement. By bridging the gap between HCP and DTC strategies, we empower brands to create synchronized marketing solutions that drive faster treatment decisions and improved patient outcomes.
Our commitment to privacy-safe, patient-centric technology ensures that every interaction is designed to make a meaningful impact, delivering life-changing therapies to the right patients at the right time. Headquartered in Waltham, Massachusetts, OptimizeRx partners with some of the world’s leading pharmaceutical and life sciences companies to transform the healthcare landscape and create a healthier future for all.
For more information, follow the Company on X, LinkedIn or visit www.optimizerx.com.
Important Cautions Regarding Forward-Looking Statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipates”, “believes”, “estimates”, “expects”, “forecasts”, “intends”, “plans”, “projects”, “targets”, “designed”, “could”, “may”, “should”, “will” or other similar words and expressions are intended to identify these forward-looking statements. All statements that reflect the Company’s expectations, assumptions, projections, beliefs or opinions about the future, other than statements of historical fact, are forward-looking statements, including, without limitation, statements relating to the Company’s future performance, expected revenues, expected Adjusted EBITDA, plans to grow shareholder value creation, plans to continue the Company’s growth and transformation, plans to position the Company to become a sustained “Rule of 40” company, increased market volatility, engagement across the Company’s network, improving interoperability between disparate point-of-care platforms, growing shift toward complex specialty medications, advancements in AI, plans to pay down debt at an accelerated rate, momentum extending into 2026, setting the stage for sustained strength in 2026 and beyond, the timing and amount of repurchases of our common stock and other statements relating to future performance, plans, and expectations. These forward-looking statements are based on the Company’s current expectations and involve assumptions regarding the Company’s business, the economy, and other future conditions that may never materialize or may prove to be incorrect. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties including, but not limited to, the effect of government regulation, seasonal trends, dependence on a concentrated group of customers, cybersecurity incidents that could disrupt operations, the ability to keep pace with growing and evolving technology, the ability to maintain contracts with electronic prescription platforms and electronic health records networks, competition, and other factors discussed in the Company’s Annual Report on Form 10-K for the fiscal year ended December 31, 2024, its subsequent Quarterly Reports on Form 10-Q, and in other filings the Company has made and may make with the Securities and Exchange Commission in the future. One should not place undue reliance on these forward-looking statements, which speak only as of the date on which they were made. The Company undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made, except as may be required by law.
OptimizeRx Contact
Andy D’Silva, Chief Business Officer
adsilva@optimizerx.com
Investor Relations Contact
Steven Halper
LifeSci Advisors, LLC
shalper@lifesciadvisors.com
| OPTIMIZERX CORPORATION CONSOLIDATED BALANCE SHEETS (in thousands, except share and per share data) | ||||||||
| December 31, | ||||||||
| 2025 | 2024 | |||||||
| ASSETS | ||||||||
| Current assets | ||||||||
| Cash and cash equivalents | $ | 23,365 | $ | 13,380 | ||||
| Accounts receivable, net of allowance for credit losses of 2025 and 2024, respectively | 37,752 | 38,212 | ||||||
| Taxes receivable | 752 | — | ||||||
| Prepaid expenses and other | 2,846 | 2,379 | ||||||
| Total current assets | 64,715 | 53,971 | ||||||
| Property and equipment, net | 106 | 150 | ||||||
| Other assets | ||||||||
| Goodwill | 70,869 | 70,869 | ||||||
| Patent rights, net | 4,586 | 5,517 | ||||||
| Technology assets, net | 6,870 | 8,180 | ||||||
| Tradename and customer relationships, net | 29,340 | 31,819 | ||||||
| Operating lease right-of-use assets | 404 | 366 | ||||||
| Security deposits and other assets | 28 | 296 | ||||||
| Total other assets | 112,097 | 117,047 | ||||||
| TOTAL ASSETS | $ | 176,918 | $ | 171,168 | ||||
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||||||
| Current liabilities | ||||||||
| Current portion of long-term debt | $ | 4,255 | $ | 2,000 | ||||
| Accounts payable | 1,636 | 2,156 | ||||||
| Accrued expenses | 11,591 | 8,486 | ||||||
| Revenue share payable | 3,086 | 5,053 | ||||||
| Taxes payable | — | 318 | ||||||
| Current portion of lease liabilities | 193 | 168 | ||||||
| Deferred revenue | 503 | 473 | ||||||
| Total current liabilities | 21,264 | 18,654 | ||||||
| Non-current liabilities | ||||||||
| Long-term debt, net | 21,421 | 30,816 | ||||||
| Lease liabilities, net of current portion | 234 | 209 | ||||||
| Deferred tax liabilities, net | 5,705 | 4,491 | ||||||
| Total liabilities | 48,624 | 54,170 | ||||||
| Commitments and contingencies | ||||||||
| Stockholders’ equity | ||||||||
| Preferred stock, outstanding at December 31, 2025 and 2024, respectively | — | — | ||||||
| Common stock, 20,194,697 shares issued at December 31, 2025 and 2024, respectively | 20 | 20 | ||||||
| Treasury stock, 2024 | (2 | ) | (2 | ) | ||||
| Additional paid-in-capital | 207,512 | 201,348 | ||||||
| Accumulated deficit | (79,236 | ) | (84,368 | ) | ||||
| Total stockholders’ equity | $ | 128,294 | $ | 116,998 | ||||
| TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY | $ | 176,918 | $ | 171,168 | ||||
| OPTIMIZERX CORPORATION CONSOLIDATED STATEMENTS OF OPERATIONS (in thousands, except share and per share data) | ||||||||||||||||
| For the Three Months Ended December 31, | For the Year Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net revenue | $ | 32,239 | $ | 32,317 | $ | 109,429 | $ | 92,127 | ||||||||
| Cost of revenues, exclusive of depreciation and amortization presented separately below | 8,139 | 10,293 | 35,834 | 32,749 | ||||||||||||
| Gross profit | 24,100 | 22,024 | 73,595 | 59,378 | ||||||||||||
| Operating expenses | ||||||||||||||||
| Stock-based compensation | 1,960 | 2,937 | 6,962 | 11,467 | ||||||||||||
| Impairment charges | 368 | — | 368 | 7,489 | ||||||||||||
| Depreciation and amortization | 1,078 | 1,094 | 4,327 | 4,329 | ||||||||||||
| Other general and administrative expenses | 12,125 | 14,358 | 50,245 | 49,799 | ||||||||||||
| Total operating expenses | 15,531 | 18,389 | 61,902 | 73,084 | ||||||||||||
| Income (loss) from operations | 8,569 | 3,635 | 11,693 | (13,706 | ) | |||||||||||
| Other income (expense) | ||||||||||||||||
| Interest expense | (1,241 | ) | (1,563 | ) | (5,294 | ) | (6,160 | ) | ||||||||
| Other income | 59 | 41 | 198 | 152 | ||||||||||||
| Interest income | 84 | 96 | 353 | 329 | ||||||||||||
| Total other expenses, net | (1,098 | ) | (1,426 | ) | (4,743 | ) | (5,679 | ) | ||||||||
| Income (loss) before provision for income taxes | 7,471 | 2,209 | 6,950 | (19,385 | ) | |||||||||||
| Income tax expense | (2,451 | ) | (2,286 | ) | (1,818 | ) | (725 | ) | ||||||||
| Net income (loss) | $ | 5,020 | $ | (77 | ) | $ | 5,132 | $ | (20,110 | ) | ||||||
| Weighted average number of shares outstanding – basic | 18,661,212 | 18,418,519 | 18,555,343 | 18,292,935 | ||||||||||||
| Weighted average number of shares outstanding – diluted | 19,381,024 | 18,418,519 | 18,998,463 | 18,292,935 | ||||||||||||
| Income (loss) per share – basic | $ | 0.27 | $ | — | $ | 0.28 | $ | (1.10 | ) | |||||||
| Income (loss) per share – diluted | $ | 0.26 | $ | — | $ | 0.27 | $ | (1.10 | ) | |||||||
| OPTIMIZERX CORPORATION CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) | ||||||||
| For the Year Ended December 31, | ||||||||
| 2025 | 2024 | |||||||
| OPERATING ACTIVITIES: | ||||||||
| Net income (loss) | $ | 5,132 | $ | (20,110 | ) | |||
| Adjustments to reconcile net income (loss) to net cash provided by operating activities: | ||||||||
| Depreciation and amortization | 4,327 | 4,329 | ||||||
| Impairment charges | 368 | 7,489 | ||||||
| Bad debt expense | — | 208 | ||||||
| Stock-based compensation | 6,962 | 11,467 | ||||||
| Amortization of debt issuance costs | 1,110 | 835 | ||||||
| Change in: | ||||||||
| Accounts receivable | 460 | (2,168 | ) | |||||
| Prepaid expenses and other assets | (467 | ) | 811 | |||||
| Accounts payable | (520 | ) | (72 | ) | ||||
| Revenue share payable | (1,967 | ) | (453 | ) | ||||
| Accrued expenses and other liabilities | 3,374 | 1,053 | ||||||
| Operating lease liabilities | 12 | — | ||||||
| Taxes receivable and payable | (1,070 | ) | — | |||||
| Deferred tax liabilities | 1,214 | 1,449 | ||||||
| Deferred loan fees | (250 | ) | (250 | ) | ||||
| Deferred revenue | 30 | 301 | ||||||
| NET CASH PROVIDED BY OPERATING ACTIVITIES | 18,715 | 4,889 | ||||||
| INVESTING ACTIVITIES: | ||||||||
| Purchases of property and equipment | (58 | ) | (112 | ) | ||||
| Capitalized software development costs | 126 | (338 | ) | |||||
| NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES | 68 | (450 | ) | |||||
| FINANCING ACTIVITIES: | ||||||||
| Repayment of long-term debt | (8,000 | ) | (4,000 | ) | ||||
| Cash paid for employee withholding taxes related to the vesting of restricted stock units | (1,150 | ) | (911 | ) | ||||
| Proceeds from exercise of stock options, net of cash paid for withholding taxes | 352 | — | ||||||
| NET CASH USED IN FINANCING ACTIVITIES | (8,798 | ) | (4,911 | ) | ||||
| NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS | 9,985 | (472 | ) | |||||
| CASH AND CASH EQUIVALENTS – BEGINNING OF PERIOD | 13,380 | 13,852 | ||||||
| CASH AND CASH EQUIVALENTS – END OF PERIOD | $ | 23,365 | $ | 13,380 | ||||
| SUPPLEMENTAL CASH FLOW INFORMATION: | ||||||||
| Cash paid for interest | $ | 4,184 | $ | 6,203 | ||||
| Cash paid for income taxes | $ | 1,760 | $ | 161 | ||||
| OPTIMIZERX CORPORATION RECONCILIATION OF GAAP TO NON-GAAP FINANCIAL MEASURES (in thousands, except share and per share data, unaudited) |
This earnings release includes certain financial measures not derived in accordance with generally accepted accounting principles (GAAP). These non-GAAP financial measures are measures of performance not defined by accounting principles generally accepted in the United States and should be considered in addition to, not in lieu of, GAAP reported measures. Additionally, these non-GAAP measures may not be comparable to similarly titled measures reported by other companies. However, management believes that presenting certain non-GAAP financial measures provides additional information to facilitate comparison of the Company's historical operating results and trends in its underlying operating results and provides transparency on how the Company evaluates its business. Management uses these non-GAAP financial measures in making financial, operating and planning decisions and in evaluating the Company's performance. Management believes that financial information excluding certain items that are not considered to reflect the Company’s ongoing operating results, such as those listed below, improves the comparability of year-to-year results. Consequently, management believes that investors may be able to better understand the Company’s operating results excluding these items. Non-GAAP financial measures may reflect adjustments for items such as asset impairment charges, amortization, stock-based compensation, acquisition expenses, severance tied to executive departures and reduction in force initiatives, shareholder activist related fees, CEO search fees, other income, as well as other items that management believes are not related to the Company’s ongoing performance.
| For the Three Months Ended December 31, | For the Twelve Months Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net income (loss) | $ | 5,020 | $ | (77 | ) | $ | 5,132 | $ | (20,110 | ) | ||||||
| Deferred income taxes | 153 | 1,215 | 153 | |||||||||||||
| Depreciation and amortization | 1,078 | 1,094 | 4,327 | 4,329 | ||||||||||||
| Stock-based compensation | 1,960 | 2,937 | 6,962 | 11,467 | ||||||||||||
| Impairment charges | 368 | — | 368 | 7,489 | ||||||||||||
| Severance charges | — | 1,183 | 275 | 1,908 | ||||||||||||
| Shareholder activist related fees | — | — | 451 | — | ||||||||||||
| CEO search fees | — | — | 225 | — | ||||||||||||
| Other income | (59 | ) | (40 | ) | (198 | ) | (152 | ) | ||||||||
| Amortization of debt issuance costs | 325 | 288 | 1,110 | 835 | ||||||||||||
| Acquisition expense | — | — | — | 243 | ||||||||||||
| Non-GAAP net income | 5,538 | 19,867 | 6,162 | |||||||||||||
| Non-GAAP net income per share | ||||||||||||||||
| Diluted | $ | 0.51 | $ | 0.30 | $ | 1.05 | $ | 0.33 | ||||||||
| Weighted average shares outstanding: | ||||||||||||||||
| Diluted | 19,381,024 | 18,464,605 | 18,998,463 | 18,583,936 | ||||||||||||
| For the Three Months Ended December 31, | For the Twelve Months Ended December 31, | |||||||||||||||
| 2025 | 2024 | 2025 | 2024 | |||||||||||||
| Net income (loss) | $ | 5,020 | $ | (77 | ) | $ | 5,132 | $ | (20,110 | ) | ||||||
| Depreciation and amortization | 1,078 | 1,094 | 4,327 | 4,329 | ||||||||||||
| Stock-based compensation | 1,960 | 2,937 | 6,962 | 11,467 | ||||||||||||
| Impairment charges | 368 | — | 368 | 7,489 | ||||||||||||
| Severance charges | — | 1,183 | 275 | 1,908 | ||||||||||||
| Acquisition expense | — | — | — | 243 | ||||||||||||
| Shareholder activist related fees | — | — | 451 | — | ||||||||||||
| CEO search fees | — | — | 225 | — | ||||||||||||
| Other income | (59 | ) | (40 | ) | (198 | ) | (152 | ) | ||||||||
| Interest expense (income), net | 1,157 | 1,466 | 4,941 | 5,831 | ||||||||||||
| Income tax expense | 2,451 | 2,286 | 1,818 | 725 | ||||||||||||
| Adjusted EBITDA | 11,975 | 8,849 | 24,301 | 11,730 | ||||||||||||
FAQ
What were OptimizeRx (OPRX) Q4 2025 revenue and adjusted EBITDA results?
How did OptimizeRx (OPRX) perform for the full year 2025 and what was the revenue growth?
What guidance did OptimizeRx (OPRX) provide for fiscal 2026 revenue and adjusted EBITDA?
What is the size and timing of OptimizeRx's (OPRX) share repurchase program?
How did OptimizeRx (OPRX) cash and operating cash flow change in 2025?
What key KPI changes did OptimizeRx (OPRX) report for 2025 that investors should watch?
